Citadel Advisors’s Lantern Pharma LTRN Stock Holding History

Citadel Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,300	Closed	-$4.6K	–	13984
2025 Q1	$4.6K	Buy	1,300 +700	+117%	+$2.9K	﹤0.01%	13880
2024 Q4	$1.91K	Sell	600 -5,500	-90%	-$18.8K	﹤0.01%	14131
2024 Q3	$22.4K	Buy	6,100 +500	+9%	+$2.06K	﹤0.01%	12699
2024 Q2	$26.2K	Sell	5,600 -2,800	-33%	-$16.8K	﹤0.01%	12401
2024 Q1	$73.9K	Buy	8,400 +8,000	+2,000%	+$42.7K	﹤0.01%	11750
2023 Q4	$1.71K	Sell	400 -6,400	-94%	-$22.6K	﹤0.01%	13784
2023 Q3	$23.2K	Buy	6,800 +6,600	+3,300%	+$30K	﹤0.01%	12504
2023 Q2	$1.13K	Sell	200 -200	-50%	-$1.03K	﹤0.01%	13983
2023 Q1	$1.93K	Hold	400	–	–	﹤0.01%	14231
2022 Q4	$2.42K	Sell	400 -14,100	-97%	-$70.6K	﹤0.01%	14341
2022 Q3	$69K	Buy	+14,500	New	+$77.9K	﹤0.01%	11405

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Citadel Advisors's LTRN Position: Q2 2026 in Review

Citadel Advisors opened a new position in Lantern Pharma (LTRN) in Q2 2026: 47,895 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #12071 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LTRN as recently as Q4 2025.

Citadel Advisors first reported a position in LTRN in Q1 2021 and has held it in 12 quarters since. The position peaked at $203K in Q1 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

Citadel Advisors held 47,895 shares of Lantern Pharma worth $200K as of Q2 2026.
Lantern Pharma was a new Citadel Advisors position in Q2 2026.
Lantern Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12071 holding.
Citadel Advisors first reported a position in Lantern Pharma in Q1 2021 and has held it in 12 quarters since.
Citadel Advisors's Lantern Pharma position peaked at $203K in Q1 2021.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.